Clinical Trials List
2022-11-15 - 2034-07-12
Others
Recruiting8
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
xxxxxx
-
Trial Applicant
Syneos Health
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/11/13
Investigators and Locations
Co-Principal Investigator
- Chi-Lu Chiang 無
- YEN-HAN TSENG 無
- 廖映庭 無
- Yuh-Min Chen 無
- 蕭慈慧 無
- 張毓帆 無
- 趙恒勝 無
- Chia-I Shen 無
- Hsu-ching Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jih-Hsiang Lee 無
- 徐偉勛 無
- James Chih-Hsin Yang 無
- 蔡子修 無
- 吳尚俊 無
- Chia-Chi Lin 無
- 黃俊凱 無
- 廖斌志 無
- Chong-Jen Yu 無
- 林昭文 無
- 陳冠宇 無
- 廖唯昱 無
- CHAO-CHI HO CHAO-CHI HO 無
- YEN-TING LIN 無
- 許嘉林 無
- 楊景堯 無
- 錢穎群 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shang-Yin Wu 無
- Seu-Chun Yang 無
- Chian-Wei Chen 無
- Wu-Chou Su 無
- Po-Lan Su 無
- Chin-Wei Kuo 無
- 蔡政軒 無
- Chun-Hui Lee 無
- Yu-Min Yeh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tzeon-jye Chiou 無
- Yu-Tien Tzeng 無
- 吳正友 無
- 陳俊佑 無
- HsingJin Eugene Liu 無
- 江振源 無
- Chia-Lun Chang 無
- 趙興隆 無
- Kuan-Jen Bai 無
- Jer-Hwa Chang 無
- Tzu-Yao Liao 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林定佑 無
- Chih-Hsi Kuo 無
- 枋岳甫 無
- Ping-Chih Hsu 無
- Chih-Liang Wang 無
- 柯皓文 無
- Chien-Ying Liu 無
- 邱立忠 無
- Chih-Hung Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Alectinib
Entrectinib
Entrectinib
Pralsetinib
Dosage Form
130
130
130
270
Dosage
150-mg capsules
100-mg capsules
200-mg capsules
100-mg capsules
500 mg/10 ml
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
21 participants
-
Global
320 participants
